Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Nuvectis Pharma in a research note issued to investors on Tuesday, February 25th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright currently has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma's Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.87) EPS and FY2028 earnings at ($2.24) EPS.
Nuvectis Pharma Price Performance
Nuvectis Pharma stock traded up $0.20 during midday trading on Friday, reaching $6.34. 69,970 shares of the company traded hands, compared to its average volume of 113,269. Nuvectis Pharma has a 12 month low of $4.44 and a 12 month high of $12.10. The firm has a market capitalization of $148.31 million, a price-to-earnings ratio of -5.47 and a beta of 0.22. The business has a 50 day moving average of $6.34 and a two-hundred day moving average of $6.41.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).
Hedge Funds Weigh In On Nuvectis Pharma
Institutional investors and hedge funds have recently made changes to their positions in the business. Baldwin Wealth Partners LLC MA raised its position in Nuvectis Pharma by 104.4% in the fourth quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company's stock worth $1,926,000 after acquiring an additional 181,831 shares during the period. Geode Capital Management LLC increased its stake in shares of Nuvectis Pharma by 49.8% in the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company's stock worth $501,000 after purchasing an additional 26,489 shares in the last quarter. Nations Financial Group Inc. IA ADV raised its holdings in Nuvectis Pharma by 35.0% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company's stock worth $73,000 after purchasing an additional 3,500 shares during the period. Forbes J M & Co. LLP lifted its position in Nuvectis Pharma by 21.9% during the fourth quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company's stock valued at $319,000 after purchasing an additional 10,599 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Nuvectis Pharma during the fourth quarter valued at about $103,000. Hedge funds and other institutional investors own 96.77% of the company's stock.
Insider Activity
In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri purchased 240,000 shares of Nuvectis Pharma stock in a transaction dated Friday, February 7th. The stock was purchased at an average price of $5.00 per share, with a total value of $1,200,000.00. Following the transaction, the insider now directly owns 2,884,121 shares of the company's stock, valued at $14,420,605. This trade represents a 9.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought 261,500 shares of company stock valued at $1,300,825 in the last ninety days. 35.78% of the stock is currently owned by company insiders.
Nuvectis Pharma Company Profile
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Featured Articles
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
